SLXN — Silexion Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Silexion Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Cash and Short Term Investments | 8.26 | 4.59 | 1.19 | 5.99 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 8.84 | 4.98 | 2.25 | 6.64 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0.464 | 0.247 | 0.56 | 0.437 |
| Other Long Term Assets | ||||
| Total Assets | 9.33 | 5.26 | 2.86 | 7.21 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 1.61 | 2.2 | 3.52 | 2.76 |
| Long Term Debt | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Minority Interest | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 5.35 | 5.67 | 6.85 | 4.61 |
| Redeemable Preferred Stock | ||||
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | 3.98 | -0.419 | -3.99 | 2.6 |
| Total Liabilities & Shareholders' Equity | 9.33 | 5.26 | 2.86 | 7.21 |
| Total Common Shares Outstanding |